Printed From BioPortfolio.com
French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia
04:52 EST 8 Dec 2017 | Labiotech.eu
Erytech’s candidate, Graspa, has been unable to significantly improve overall survival in patients with acute myeloid leukemia during a Phase IIb trial. Erytech, based in Lyon, France, has developed an interesting approach to delivering drugs for the treatment of cancer and orphan diseases. ...
This awesome article French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia
